Efficacy, Safety, and Tolerability of Approved Combination BRAF and MEK Inhibitor Regimens for BRAF -Mutant Melanoma by Hamid, Omid, Cowey, C Lance, Offner, Michelle, Faries, Mark, Carvajal, Richard D

Get full text

Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymp... by Chanan-Khan, Asher, Prof, Cramer, Paula, MD, Demirkan, Fatih, MD, Fraser, Graeme, MD, Silva, Rodrigo Santucci, MD, Grosicki, Sebastian, Prof, Pristupa, Aleksander, MD, Janssens, Ann, MD, Mayer, Jiri, Prof, Bartlett, Nancy L, Prof, Dilhuydy, Marie-Sarah, MD, Pylypenko, Halyna, MD, Loscertales, Javier, MD, Avigdor, Abraham, MD, Rule, Simon, Prof, Villa, Diego, MD, Samoilova, Olga, MD, Panagiotidis, Panagiots, Prof, Goy, Andre, MD, Mato, Anthony, MD, Pavlovsky, Miguel A, MD, Karlsson, Claes, MD, Mahler, Michelle, MD, Salman, Mariya, PhD, Sun, Steven, PhD, Phelps, Charles, MS, Balasubramanian, Sriram, PhD, Howes, Angela, PhD, Hallek, Michael, MD

Get full text

Outcomes By Refractory Status and Prior Therapies Received in Patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) from the ECHELON-3 Study by Hahn, Uwe, Bartlett, Nancy L., Kim, Jeong-A, Bouabdallah, Krimo, Forward, Nicholas, Chen, Tsai-Yun, Camus, Vincent, Wang, Ming-Chung, Carassou, Philippe, Derenzini, Enrico, Chang, Hung, Offner, Fritz, Ghesquieres, Herve, Nowakowski, Grzegorz S., Yasenchak, Christopher, Patterson, Monica, Ho, Linda, Rustia, Evelyn, Fanale, Michelle, Fenton, Keenan, Portell, Craig A.

Get full text

Phase IA/II, multicentre, open‐label study of the CD40 antagonistic monoclonal antibody lucatumumab in adult patients with advanced non‐Hodgkin or Hodgkin lymphoma by Fanale, Michelle, Assouline, Sarit, Kuruvilla, John, Solal‐Céligny, Philippe, Heo, Dae S., Verhoef, Gregor, Corradini, Paolo, Abramson, Jeremy S., Offner, Fritz, Engert, Andreas, Dyer, Martin J. S., Carreon, Daniel, Ewald, Brett, Baeck, Johan, Younes, Anas, Freedman, Arnold S.

Get full text

Phase IA / II , multicentre, open‐label study of the CD 40 antagonistic monoclonal antibody lucatumumab in adult patients with advanced non‐ H odgkin or H odgkin lymphoma by Fanale, Michelle, Assouline, Sarit, Kuruvilla, John, Solal‐Céligny, Philippe, Heo, Dae S., Verhoef, Gregor, Corradini, Paolo, Abramson, Jeremy S., Offner, Fritz, Engert, Andreas, Dyer, Martin J. S., Carreon, Daniel, Ewald, Brett, Baeck, Johan, Younes, Anas, Freedman, Arnold S.

Get full text

Safety Profile and Clinical Response To MEDI-551, a Humanized Monoclonal Anti-CD19, In a Phase 1/2 Study In Adults With Relapsed Or Refractory Advanced B-Cell Malignancies by Forero-Torres, Andres, Hamadani, Mehdi, Fanale, Michelle A., Bello, Celeste M., Kipps, Thomas J., Offner, Fritz, Verhoef, Gregor, Federico, Massimo, Gregory, Stephanie A., Sonet, Anne, Assouline, Sarit, Pérez de Oteyza, Jaime, Tomas, Jose Francisco, Cuneo, Antonio, Elgeioushi, Nairouz, Goswami, Trishna, Ibrahim, Ramy, Herbst, Ronald, Cheson, Bruce D.

Get full text

MEDI-551, a Humanized Monoclonal Anti-CD19, in Adults with Relapsed or Refractory Advanced B-Cell Malignancies: Results From a Phase 1/2 Study by Forero, Andres, Hamadani, Mehdi, Fanale, Michelle A., Bello, Celeste M., Kipps, Thomas J, Offner, Fritz, Verhoef, Gregor, Federico, Massimo, Gregory, Stephanie A., Sonet, Anne, Assouline, Sarit, de Oteyza, Jaime Pérez, Tomas, Jose Francisco, Cuneo, Antonio, Zhang, Weiya, Goswami, Trishna, Ibrahim, Ramy, Yao, Zhenling, Herbst, Ronald, Cheson, Bruce D.

Get full text

Varia by Abadie, Florence, Bernoux, Philippe, Besucco, Nathalie, Callon, Michel, Champy, Florent, Cochoy, Franck, Dupré, Michèle, Durand, Claude, Durand, Michelle, Juan, Salvador, Livianb, Yves-Frédéric, Offner, Jean-Marc, Rabeharisoa, Vololona, Tallard, Michèle, Thénard, Jean-Claude, Zalio, Pierre-Paul, Zarifian, Philippe

Get full text